BenzingaOctober 1, 2026 at 3:32 AM NY26 Days Ago
Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris
Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding,
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
